4207-54-9Relevant articles and documents
Rate constants for the addition of the 2-cyano-2-propyl radical to alkenes in solution
Heberger,Fischer
, p. 249 - 263 (1993)
Absolute rate constants for the addition of the 2-cyano-2-propyl radical to 26 alkenes CH2 = CXY at 315 K were determined in solution by time-resolved electron-spin-resonance spectroscopy. They vary with the alkene substituents from 30 M-1 s-1 to 7′010 M-1 s-1. For styrene the temperature dependence is given by log k/M-1 s-1 = 7.7 - 26.1/Θ where Θ = 2.303 RT in kJ/mol. An analysis of the substituent effects in terms of polar and enthalpic factors reveals a dominant influence of the overall reaction enthalpy.
SEMICONDUCTING COMPOSITIONS COMPRISING SEMICONDUCTING POLYMERS
-
Paragraph 0580-0582, (2019/05/15)
A semiconducting composition comprising a semiconducting polymer and a semiconducting non-polymeric polycyclic compound, wherein the semiconducting polymer comprises units of A and/or B: wherein R1, R2, R5, R6, R7, R8, x, y, p, q, r, R3, R4, R9, R10 and R11 have any of the meanings defined in the description.
THIAZOLYL AND OXAZOLYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS
-
Paragraph 00373, (2014/06/11)
Compounds of Formula (I) or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.
BICYCLIC HETEROARYL UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS
-
Paragraph 00488, (2014/06/11)
Compounds of Formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.